July I 2023

During a Targeted Oncology™ Clinical Case Forum™ event, Ronan J. Kelly, MD, MBA, discussed the significance of the CheckMate 9LA, KEYNOTE-407, EMPOWER-Lung 3, and POSEIDON studies which all explored immunotherapies in patients with advanced non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Nizar M. Tannir, MD, discussed with participants their experiences with the combination of lenvatinib and pembrolizumab, including the dosing schedule of pembrolizumab and finding a tolerable dose of lenvatinib.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hatem Soliman, MD, discussed how the FDA approval of elacestrant impacts the treatment setting of ER+, HER2- breast cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Ticiana Leal, MD, discussed the use of sotorasib and adagrasib in patients with KRAS G12C mutations in non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, discussed second-line therapy combinations for a patient with early-relapse multiple myeloma after complete remission with bortezomib, lenalidomide, and dexamethasone.

During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Campbell, MD, MS, discussed guidelines and available therapies for a patient who requires second-line treatment and beyond for metastatic renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, and participants discussed current approaches to treating biliary tract cancers, including the TOPAZ-1 study regimen of cisplatin, gemcitabine, and durvalumab.

During a Targeted Oncology™ Case-Based Roundtable™ event, Chakra P. Chaulagain, MD, and participants discussed how they would treat a 54-year-old woman diagnosed with transplant-eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Danko Martincic, MD, outlined the definition, risk factors, and treatment for patients with tumor lysis syndrome.

In an interview with Targeted Oncology, Arturo Loaiza-Bonilla, MD, MSEd, discussed the growing use of artificial intelligence in oncology practices. Loaiza-Bonilla is a medical oncologist and cofounder of Massive Bio, a company that uses AI to connect oncologists and patients with cancer to clinical trials of novel treatments.

At a live, virtual Case-Based Roundtable meeting, Bradley McGregor, MD, discussed with fellow physicians how best to integrate new approaches to treatment for patients with relapsed or refractory clear cell renal cell carcinoma.